Teva's Impact on the US National Patent System ("NPS"): The Mayo/Biosig/Alice ("MBA") Framework Made It a Rough Diamond -- But Rough for Ever? Teva Cuts This Diamond and Thus May Create a Historic Mega-Trend in SPL, also Internationally

At a first glance and having Markman in mind, the Supreme Court's Teva decision seems to be only a minor shift of power as to developing Substantive Patent Law ("SPL") precedents for Emerging Technology Claimed Inventions ("ET CIs") in the US NPS: A)Away from the CAFC to District Courts. Yet, this allegedly minor power shift likely launched a profound trend: B)Away from totally diverging MBA interpretations¹⁾ by CAFC boards, towards the MBA-framework²⁾ based SPL scientification. Sections V/VII show the ease of joining this MBA/Teva trend by all ET patents/applications - and of leveraging on the vast advantages it implies³⁾.